UPS Bets $48 Million on Cold-Chain Logistics Expansion

The expansion arrives as the market for temperature-sensitive biologics prepares for a projected compound annual growth rate of 8.3% through 2033. Industry analysts expect the sector to reach a valuation of roughly $39.1 billion, driven by a new generation of drugs like Novo Nordisk’s Wegovy and Ozempic that require strict refrigeration to maintain efficacy. According to World Health Organization data, cold-chain failures currently account for up to 50% of global vaccine wastage, a figure UPS intends to mitigate through improved end-to-end chain of custody.

Kate Gutmann, president of international, healthcare and supply chain solutions, noted that the initiative moves beyond standard shipping to prioritize patient outcomes. This strategy aligns with the company’s recent financial performance; in the first quarter of this year, UPS hit a record $3 billion in healthcare-related revenue. CEO Carol Tomé has identified the sector as a primary growth engine, confirming the company has gained market share annually since 2021 by prioritizing the safe delivery of critical treatments and diagnostics.